KR20140107413A - 암의 처치를 위한 이노투즈맙 오조가미신 및 토리셀의 조합 - Google Patents
암의 처치를 위한 이노투즈맙 오조가미신 및 토리셀의 조합 Download PDFInfo
- Publication number
- KR20140107413A KR20140107413A KR1020147018997A KR20147018997A KR20140107413A KR 20140107413 A KR20140107413 A KR 20140107413A KR 1020147018997 A KR1020147018997 A KR 1020147018997A KR 20147018997 A KR20147018997 A KR 20147018997A KR 20140107413 A KR20140107413 A KR 20140107413A
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- pharmaceutically acceptable
- temsirolimus
- inosituzum
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- CFPKXYRMGFVWJZ-MSOIECKFSA-N CCCc(cc1)cc([O](C)C(CCOC([C@H](CCCC2)N2C(C([C@]2(O)OC(CC(/C(/C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(C([C@@H](/C(/C)=C/C)O)OC)=O)OC)CC[C@H]2C)=O)=O)=O)=O)c1OC(C(C)(CO)CO)=O Chemical compound CCCc(cc1)cc([O](C)C(CCOC([C@H](CCCC2)N2C(C([C@]2(O)OC(CC(/C(/C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(C([C@@H](/C(/C)=C/C)O)OC)=O)OC)CC[C@H]2C)=O)=O)=O)=O)c1OC(C(C)(CO)CO)=O CFPKXYRMGFVWJZ-MSOIECKFSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161576831P | 2011-12-16 | 2011-12-16 | |
| US61/576,831 | 2011-12-16 | ||
| PCT/IB2012/056958 WO2013088304A1 (en) | 2011-12-16 | 2012-12-04 | Combination of inotuzumab ozogamicin and torisel for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177011120A Division KR20170049617A (ko) | 2011-12-16 | 2012-12-04 | 암의 처치를 위한 이노투즈맙 오조가미신 및 토리셀의 조합 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20140107413A true KR20140107413A (ko) | 2014-09-04 |
Family
ID=47557418
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177011120A Ceased KR20170049617A (ko) | 2011-12-16 | 2012-12-04 | 암의 처치를 위한 이노투즈맙 오조가미신 및 토리셀의 조합 |
| KR1020147018997A Ceased KR20140107413A (ko) | 2011-12-16 | 2012-12-04 | 암의 처치를 위한 이노투즈맙 오조가미신 및 토리셀의 조합 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177011120A Ceased KR20170049617A (ko) | 2011-12-16 | 2012-12-04 | 암의 처치를 위한 이노투즈맙 오조가미신 및 토리셀의 조합 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9642918B2 (enExample) |
| EP (1) | EP2790723A1 (enExample) |
| JP (1) | JP2013126979A (enExample) |
| KR (2) | KR20170049617A (enExample) |
| CN (1) | CN104023747A (enExample) |
| AU (2) | AU2012351728A1 (enExample) |
| BR (1) | BR112014014181A2 (enExample) |
| CA (1) | CA2859089A1 (enExample) |
| HK (1) | HK1201191A1 (enExample) |
| IL (1) | IL233165A0 (enExample) |
| MX (1) | MX2014007077A (enExample) |
| RU (1) | RU2607594C2 (enExample) |
| WO (1) | WO2013088304A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20161413A1 (es) | 2013-11-04 | 2017-01-10 | Stemcentrx Inc | Conjugados de anticuerpo anti-efna4-farmaco |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| KR20190080992A (ko) | 2015-05-21 | 2019-07-08 | 하푼 테라퓨틱스, 인크. | 삼중특이성 결합 단백질 및 사용 방법 |
| WO2016201481A1 (en) * | 2015-06-15 | 2016-12-22 | Newsouth Innovations Pty Limited | Pharmaceutical combinations of organo-arsenoxide compounds and mtor inhibitors |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| SG10202107880XA (en) | 2017-05-12 | 2021-09-29 | Harpoon Therapeutics Inc | Mesothelin binding proteins |
| JP2020524262A (ja) * | 2017-06-06 | 2020-08-13 | ザ・ジョンズ・ホプキンス・ユニバーシティ | エピジェネティック療法による合成致死性の誘導 |
| PL3694529T3 (pl) | 2017-10-13 | 2024-12-16 | Harpoon Therapeutics, Inc. | Trójswoiste białka i sposoby zastosowania |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| CN113286817B (zh) | 2018-09-25 | 2025-01-28 | 哈普恩治疗公司 | Dll3结合蛋白及使用方法 |
| US20220168343A1 (en) * | 2019-02-13 | 2022-06-02 | Coimmune, Inc. | Cancer immunotherapy using combinations of cells expressing chimeric antigen receptors and monoclonal antibodies |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| JP2022551909A (ja) * | 2019-10-10 | 2022-12-14 | ブライオロジクス インコーポレイテッド | ブリオスタチンによる腫瘍関連抗原の誘導方法 |
| KR20230035576A (ko) | 2020-07-07 | 2023-03-14 | 비온테크 에스이 | Hpv 양성 암 치료용 rna |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| AU2022312698A1 (en) | 2021-07-13 | 2024-01-25 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| CN120418289A (zh) | 2022-12-14 | 2025-08-01 | 安斯泰来制药欧洲有限公司 | 结合cldn18.2和cd3的双特异性结合剂与免疫检查点抑制剂的联合疗法 |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
| US3993749A (en) | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
| US4885171A (en) | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
| US5206018A (en) | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
| US4401653A (en) | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
| US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
| US4667637A (en) | 1986-01-08 | 1987-05-26 | Brunswick Corporation | Gated knock detector for internal-combustion engines |
| US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
| DE69209183T2 (de) | 1991-06-18 | 1996-08-08 | American Home Prod | Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| EP2591775A1 (en) * | 2006-04-05 | 2013-05-15 | Novartis AG | Combinations comprising mtor inhibitors for treating cancer |
| WO2007125252A1 (fr) | 2006-04-26 | 2007-11-08 | France Telecom | Procede et systeme de gestion d'un paiement electronique |
| GB0609378D0 (en) * | 2006-05-11 | 2006-06-21 | Novartis Ag | Organic compounds |
| BRPI0921006A2 (pt) * | 2008-11-13 | 2015-12-15 | Emergent Product Dev Seattle | terapias imunoterapêuticas combinadas de cd37 e usos destas |
| US7998973B2 (en) * | 2009-11-13 | 2011-08-16 | Aveo Pharmaceuticals, Inc. | Tivozanib and temsirolimus in combination |
| PL2515941T3 (pl) * | 2009-12-21 | 2020-04-30 | F. Hoffmann-La Roche Ag | Preparat farmaceutyczny zawierający bewacyzumab |
| JP6042801B2 (ja) * | 2010-04-27 | 2016-12-14 | ロシュ グリクアート アーゲー | ｍＴＯＲインヒビターとのアフコシル化ＣＤ２０抗体の併用療法 |
-
2012
- 2012-12-04 HK HK15101740.4A patent/HK1201191A1/xx unknown
- 2012-12-04 CA CA2859089A patent/CA2859089A1/en not_active Abandoned
- 2012-12-04 AU AU2012351728A patent/AU2012351728A1/en not_active Abandoned
- 2012-12-04 RU RU2014124005A patent/RU2607594C2/ru not_active IP Right Cessation
- 2012-12-04 EP EP12813985.4A patent/EP2790723A1/en not_active Ceased
- 2012-12-04 KR KR1020177011120A patent/KR20170049617A/ko not_active Ceased
- 2012-12-04 BR BR112014014181A patent/BR112014014181A2/pt not_active IP Right Cessation
- 2012-12-04 US US14/365,793 patent/US9642918B2/en not_active Expired - Fee Related
- 2012-12-04 KR KR1020147018997A patent/KR20140107413A/ko not_active Ceased
- 2012-12-04 MX MX2014007077A patent/MX2014007077A/es unknown
- 2012-12-04 WO PCT/IB2012/056958 patent/WO2013088304A1/en not_active Ceased
- 2012-12-04 CN CN201280062130.7A patent/CN104023747A/zh active Pending
- 2012-12-14 JP JP2012273427A patent/JP2013126979A/ja active Pending
-
2014
- 2014-06-16 IL IL233165A patent/IL233165A0/en unknown
-
2016
- 2016-04-26 AU AU2016202621A patent/AU2016202621B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN104023747A (zh) | 2014-09-03 |
| JP2013126979A (ja) | 2013-06-27 |
| US20140335109A1 (en) | 2014-11-13 |
| MX2014007077A (es) | 2015-03-06 |
| AU2016202621B2 (en) | 2017-11-02 |
| WO2013088304A1 (en) | 2013-06-20 |
| EP2790723A1 (en) | 2014-10-22 |
| CA2859089A1 (en) | 2013-06-20 |
| AU2016202621A1 (en) | 2016-05-26 |
| RU2014124005A (ru) | 2016-02-10 |
| BR112014014181A2 (pt) | 2017-06-13 |
| KR20170049617A (ko) | 2017-05-10 |
| HK1201191A1 (en) | 2015-08-28 |
| US9642918B2 (en) | 2017-05-09 |
| IL233165A0 (en) | 2014-07-31 |
| RU2607594C2 (ru) | 2017-01-10 |
| AU2012351728A1 (en) | 2014-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20140107413A (ko) | 암의 처치를 위한 이노투즈맙 오조가미신 및 토리셀의 조합 | |
| AU2016280003B2 (en) | PD-L1 antagonist combination treatments | |
| JP6784668B2 (ja) | 相乗的オーリスタチン組合せ | |
| US20200069694A1 (en) | Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1 | |
| US20230256110A1 (en) | Combination of antibody-drug conjugate and atm inhibitor | |
| KR20170122810A (ko) | 암을 치료하기 위한 pd-1 길항제 및 에리불린의 조합 | |
| JP2022191244A (ja) | 抗ｃｄ１９ ａｄｃを投与するための投与レジメ | |
| CN114302746A (zh) | 包含抗cd25抗体药物缀合物和另一剂的组合疗法 | |
| CN114302745A (zh) | 包含抗cd19抗体药物缀合物以及pi3k抑制剂或第二剂的组合疗法 | |
| US20220096436A1 (en) | Combination product for the treatment of cancer | |
| US20190211102A1 (en) | Methods and combination therapy to treat cancer | |
| EA049478B1 (ru) | Комбинация конъюгата антитела и лекарственного средства и ингибитора atr | |
| HK40070611A (en) | Combination of anti-her2 antibody and cdk inhibitor for tumor treatment | |
| HK1242995A1 (en) | Synergistic auristatin combinations | |
| NZ737018B2 (en) | Pd-l1 antagonist combination treatments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0105 | International application |
Patent event date: 20140709 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20151120 Patent event code: PE09021S01D |
|
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20160929 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20151120 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| AMND | Amendment | ||
| PX0901 | Re-examination |
Patent event code: PX09011S01I Patent event date: 20160929 Comment text: Decision to Refuse Application Patent event code: PX09012R01I Patent event date: 20160520 Comment text: Amendment to Specification, etc. |
|
| PX0601 | Decision of rejection after re-examination |
Comment text: Decision to Refuse Application Patent event code: PX06014S01D Patent event date: 20170120 Comment text: Amendment to Specification, etc. Patent event code: PX06012R01I Patent event date: 20161229 Comment text: Decision to Refuse Application Patent event code: PX06011S01I Patent event date: 20160929 Comment text: Amendment to Specification, etc. Patent event code: PX06012R01I Patent event date: 20160520 Comment text: Notification of reason for refusal Patent event code: PX06013S01I Patent event date: 20151120 |
|
| J201 | Request for trial against refusal decision | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20170424 |
|
| PJ0201 | Trial against decision of rejection |
Patent event date: 20170424 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20170120 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Patent event date: 20160929 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20180620 Appeal identifier: 2017101001981 Request date: 20170424 |
|
| J301 | Trial decision |
Free format text: TRIAL NUMBER: 2017101001981; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20170424 Effective date: 20180620 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S01D Patent event date: 20180620 Comment text: Trial Decision on Objection to Decision on Refusal Appeal kind category: Appeal against decision to decline refusal Request date: 20170424 Decision date: 20180620 Appeal identifier: 2017101001981 |